Search results for "Improved survival"

showing 7 items of 17 documents

Prevalence of HPV infection in racial-ethnic subgroups of head and neck cancer patients

2017

Abstract The landscape of human papillomavirus (HPV) infection in racial/ethnic subgroups of head and neck cancer (HNC) patients has not been evaluated carefully. In this study, a meta-analysis examined the prevalence of HPV in HNC patients of African ancestry. Additionally, a pooled analysis of subject-level data was also performed to investigate HPV prevalence and patterns of p16 (CDNK2A) expression amongst different racial groups. Eighteen publications (N = 798 Black HNC patients) were examined in the meta-analysis, and the pooled analysis included 29 datasets comprised of 3129 HNC patients of diverse racial/ethnic background. The meta-analysis revealed that the prevalence of HPV16 was h…

OncologyOROPHARYNGEAL CANCERHPVCancer Researchmedicine.medical_specialtyEthnic groupUNITED-STATESOriginal Manuscript03 medical and health sciences0302 clinical medicineInternal medicinemedicineP16 IMMUNOHISTOCHEMISTRYHuman papillomavirus030223 otorhinolaryngologyEPSTEIN-BARR-VIRUSE6/E7 MESSENGER-RNAAFRICAN-AMERICANSHUMAN-PAPILLOMAVIRUS TYPE-16IMPROVED SURVIVALbusiness.industryPOTENTIALLY MALIGNANT DISORDERSHead and neck cancerHPV infectionCancerOrvostudományokGeneral Medicinemedicine.diseaseRacial ethnic3. Good healthPooled analysis030220 oncology & carcinogenesisSmoking statusSettore MED/31 - OTORINOLARINGOIATRIASQUAMOUS-CELL CARCINOMAEgészségtudományokbusiness
researchProduct

Immunotherapeutic Advances for NSCLC.

2021

Abstract Immunotherapy with antibodies against PD-1 or PD-L1, either alone or in combination with chemotherapy, has revolutionized treatment paradigms of non-small cell lung cancer (NSCLC) patients without oncogenic driver alterations. These agents, namely immune checkpoint inhibitors (ICIs), have also widely demonstrated a remarkable efficacy in locally advanced as well as in early-stage NSCLC. Assessment of tumor PD-L1 expression by immunohistochemistry has entered into routine clinical practice to select patients for immunotherapy, even though its predictive role has long been debated. Despite improved survival outcomes over standard chemotherapy, treatment with ICIs is associated with i…

OncologyResponse rate (survey)medicine.medical_specialtyTumor microenvironmentChemotherapybusiness.industryImmune checkpoint inhibitorsmedicine.medical_treatmentGastroenterologyImproved survivalDiseaseImmunotherapyReviewanti-PD-1/PD-L1 antibodiesOncologyRheumatologyInternal medicineImmunology and AllergyMedicinePharmacology (medical)immunotherapybusinessnon-small cell lung cancerPredictive biomarkerBiologics : targetstherapy
researchProduct

270 Increased hospital mortality in HIV-infected patients with acute coronary or cerebrovascular syndromes. Analysis from a French nationwide hospita…

2011

Background After more than two decades of the AIDS epidemic, the spectrum of HIV-associated vascular diseases has considerably evolved from infectious disease with improved survival, to premature atherosclerosis. As a consequence, acute atherosclerosis complications, such as acute coronary and cerebrovascular syndromes (ACS and CVS) are currently growing. However, only few data are available on HIV-infected patients in the setting of ACS/CVS. The aim of the present study was to determine the prevalence of HIV, as well as the characteristics and hospital case fatality of HIV-infected patients with CVS and ACS. Methods From the French nationwide hospital medical information database, data fro…

Pediatricsmedicine.medical_specialtyVascular diseasebusiness.industryImproved survivalMedical informationHospital mortalitymedicine.diseasePremature atherosclerosisAcquired immunodeficiency syndrome (AIDS)Case fatality ratemedicineHiv infected patientsbusinessCardiology and Cardiovascular MedicineArchives of Cardiovascular Diseases Supplements
researchProduct

Nutritional assessment in preterm infants with special reference to body composition

2001

In recent years, improvements in care have significantly improved survival in preterm and, particularily, the very low birth weight infant (VLBW). While immediate survival can be directly related to pulmonary maturity, several studies stress the importance of timely and adequate nutrition in these high-risk infants on a short- and long-term [1]. Yet, nutritional support remains a very controversial issue in these high-risk infants. Early provision of adequate intakes may be limited by clinical instability and immaturity. At the same time, nutritional requirements and methods of nutritional assessment are not well defined. The aim of this paper is to outline some of the methods used during n…

Pediatricsmedicine.medical_specialtybusiness.industryBody WeightInfant NewbornImproved survivalBody HeightSkinfold ThicknessLow birth weightAbsorptiometry PhotonNutrition AssessmentAnimals NewbornBone DensityPediatrics Perinatology and Child HealthBody CompositionmedicineAnimalsHumansmedicine.symptomEnergy MetabolismInfant Nutritional Physiological PhenomenabusinessWeight gainInfant PrematureSeminars in Neonatology
researchProduct

A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension

2021

Background Diagnostic delay of chronic thromboembolic pulmonary hypertension (CTEPH) exceeds 1 year, contributing to higher mortality. Health economic consequences of late CTEPH diagnosis are unknown. We aimed to develop a model for quantifying the impact of diagnosing CTEPH earlier on survival, quality-adjusted life-years (QALYs) and healthcare costs. Material and methods A Markov model was developed to estimate lifelong outcomes, depending on the degree of delay. Data on survival and quality of life were obtained from published literature. Hospital costs were assessed from patient records (n=498) at the Amsterdam UMC – VUmc, which is a Dutch CTEPH referral center. Medication costs were ba…

Pulmonary and Respiratory Medicine7medicine.medical_specialtyRespiratory SystemImproved survival610 Medicine & healthQuality of lifeQUALITY-OF-LIFEOriginal Research ArticlesHealth caremedicineEconomic impact analysisIntensive care medicineANGIOPLASTYEconomic consequencesDisease burdenPulmonary Vascular DiseaseScience & Technologybusiness.industry10031 Clinic for AngiologyR2740 Pulmonary and Respiratory MedicineReferral centerMedicineChronic thromboembolic pulmonary hypertensionbusinessLife Sciences & Biomedicine
researchProduct

Geographical Disparities in Multiple Myeloma Survival in Three French Regions

2016

Abstract Introduction: Within the past decade, new therapeutic agents for Multiple Myeloma (MM) have improved survival of patients included in clinical trials. The aim of this study was to measure and compare characteristics and survival of patients with MM in different French regions in the general population. Methods: All incident cases with MM (ICD-O-3 codes, 9732/3 and) between January 1, 2008 and December 31, 2009 in the French population-based Hematological Malignancies registries (Calvados, Côte d'Or and Gironde) were included. The end point of follow-up was January 1, 2015. Specific clinical information was recorded from clinical charts. Incidence rates were calculated using estimat…

education.field_of_studyPediatricsmedicine.medical_specialtyMultivariate analysisAnemiabusiness.industryImmunologyPopulationImproved survivalCell BiologyHematologymedicine.diseaseBiochemistryClinical trialmedicinebusinesseducationNet SurvivalSex ratioMultiple myelomaDemographyBlood
researchProduct

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myelo…

2018

Abstract Introduction: Mutations localized in the tyrosine kinase domain activation loop of FLT3 (FLT3-TKD), representing point mutations in codon D835/I836 and rarely deletions of codon I836, induce constitutive tyrosine phosphorylation and activation of the receptor tyrosine kinase similarly to FLT3 internal tandem duplication (ITD) mutations. However, the prognostic role of FLT3-TKD in AML, particularly in the presence of NPM1 mutations, is not well established. The phase 3 RATIFY trial [NCT00651261; Stone et al. N Engl J Med. 2017] showed that in combination with standard chemotherapy, midostaurin (PKC412) improved survival outcomes across all 3 FLT3 stratification subgroups (ITD high a…

medicine.medical_specialtybusiness.industryImmunologyComplete remissionImproved survivalCell BiologyHematologyNewly diagnosedPlaceboBiochemistryConsolidation therapy03 medical and health sciencesNPM1 Mutationchemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisFamily medicineMedicineIn patientMidostaurinbusiness030215 immunologyBlood
researchProduct